Silence Therapeutics plc Stock London S.E.
Stocks
GB0008433350
Biotechnology & Medical Research
OTC Markets Traded|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| Market Cap | 392M 523M 465M 431M 739M 49.6B 751M 5.18B 2.03B 25.88B 1.96B 1.92B 82.51B | P/E 2026 * |
-17x | P/E 2027 * | -14x |
|---|---|---|---|---|---|
| Enterprise Value | 259M 345M 307M 284M 488M 32.75B 496M 3.42B 1.34B 17.09B 1.3B 1.27B 54.48B | EV / Sales 2026 * |
796x | EV / Sales 2027 * | 290x |
| Free-Float |
69.35% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Silence Therapeutics plc
| Manager | Title | Age | Since |
|---|---|---|---|
Iain Ross
CEO | Chief Executive Officer | 72 | 2025-11-30 |
Rhonda Hellums
DFI | Director of Finance/CFO | 54 | 2022-01-31 |
Curtis Rambaran
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
David Lemus
BRD | Director/Board Member | 63 | 2018-06-20 |
Iain Ross
CHM | Chairman | 72 | 2003-12-31 |
Tim McInerney
BRD | Director/Board Member | 65 | 2025-05-04 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.60% | -8.56% | +49.38% | +63.51% | 65B | |
| +0.03% | +5.56% | +9.10% | +69.05% | 51.2B | |
| -4.09% | -0.11% | +2.22% | +53.15% | 51.19B | |
| -1.53% | +2.70% | +30.48% | +34.12% | 43.93B | |
| -1.34% | +4.12% | +16.64% | +115.13% | 41.96B | |
| -5.97% | -6.22% | +228.95% | +454.22% | 38.14B | |
| +6.53% | +8.02% | +16.40% | +53.41% | 33.24B | |
| -0.90% | -10.49% | +37.09% | -3.70% | 25.2B | |
| -1.07% | +2.33% | +19.43% | +9.98% | 22.5B | |
| Average | -1.66% | -0.35% | +45.52% | +94.32% | 41.37B | |
| Weighted average by Cap. | -2.20% | -0.50% | +44.25% | +96.53% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 325K 434K 385K 357K 613K 41.15M 623K 4.29M 1.68M 21.47M 1.63M 1.59M 68.45M | 751K 1M 890K 825K 1.42M 95.03M 1.44M 9.92M 3.89M 49.59M 3.76M 3.68M 158M |
| Net income | -42.18M -56.27M -50.02M -46.36M -79.6M -5.34B -80.87M -557M -218M -2.79B -211M -207M -8.88B | -64.3M -85.78M -76.25M -70.67M -121M -8.14B -123M -849M -333M -4.25B -322M -315M -13.54B |
| Net Debt | -133M -178M -158M -146M -251M -16.85B -255M -1.76B -689M -8.79B -666M -652M -28.03B | -174M -232M -206M -191M -328M -22.04B -334M -2.3B -902M -11.5B -871M -853M -36.66B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
